The Role of ITGAM in Systemic Lupus Erythematosus

TAP0307.6: Sub-study of TAP 0307- Enrollment of Normal Controls to Study the Role of ITGAM in Systemic Lupus Erythematosus

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01230112

Enrollment

Registered

2010-10-28

Start date

2009-12-31

Completion date

2012-04-30

Last updated

2013-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Lupus Erythematosus

Brief summary

Study to examine the role of ITGAM molecule in normal control subjects with known genetic variation in the ITGAM gene.

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Yes

Inclusion criteria

* males and females, age 18 or older, enrolled in Genotype and Phenotype Registry, in general good health * Participants who carry the genotype of interest, based on a buccal or blood derived DNA sample

Exclusion criteria

* History of Systemic Lupus Erythematosus, rheumatoid arthritis, or other autoimmune disease * History of cancer or lymphoma * Current use of aspirin, prednisone, or NSAID or any immunosuppressant * Self reported HIV

Countries

United States

Outcome results